论文信息 - Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies - 字舞流文

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

I. Flinn | B. Keyt | C. Takimoto | Sung-Soo Yoon | W. Kim | C. Cheah | M. Leabman | M. Kotturi | G. Gregory | M. Matasar | C. Diefenbach | J. So | L. Nastoupil | A. Gopal | P. Armand | K. Logronio | E. Budde | M. Ku | I. Qazi | I. Sison | Thomas Manley | G. Hernandez